Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

BCL-2 protein overexpression, common in B-cell acute lymphoblastic leukemia (B-ALL), including the Philadelphia (Ph)-like subtype, mediates leukemic cell survival. We treated 24 patients with 14 days of BCL-2 inhibitor, venetoclax, 400 mg daily (dose level 1) during induction and consolidation cycl...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ibrahim Aldoss, Jianying Zhang, Kathryn Shimamoto, Caner Saygin, Marjorie Robbins, Vaibhav Agrawal, Ahmed Aribi, Diren Arda Karaoglu, Hoda Pourhassan, Paul Koller, Haris Ali, Amanda Blackmon, Salman Otoukesh, Karamjeet Sandhu, Brian Ball, Andrew S. Artz, Monzr M. Al Malki, Amandeep Salhotra, Jose Tinajero, Zhaohui Gu, Ian Lagman, Michelle Velasquez, Jacqueline Dang, Pamela S. Becker, Michelle Afkhami, Lucy Ghoda, Wendy Stock, Stephen J Forman, Anthony Stein, Guido Marcucci, Vinod Pullarkat
Formato:	Artigo
Idioma:	Inglês
Publicado:	Ferrata Storti Foundation 2024-11-01
Series:	Haematologica
Acceso en liña:	https://haematologica.org/article/view/11817
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!